Suppr超能文献

[三种预后评分系统对评估慢性髓性白血病患者预后的疗效]

[Efficacy of three prognostic scoring systems on evaluating the prognosis for patients with chronic myeloid leukemia].

作者信息

Huang Jing, Zhao Xielan

机构信息

Department of Hematology, Xiangya Hospital, Central South University, Changsha 410008, China.

出版信息

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2016 Aug;41(8):809-14. doi: 10.11817/j.issn.1672-7347.2016.08.006.

Abstract

OBJECTIVE

To retrospectively analyze the efficacy of three prognostic scoring systems on evaluating the prognosis for patients with chronic myeloid leukemia (CML) in chronic phase (CP).

METHODS

In this retrospective cohort study, we collected 234 patients with CML in CP, who were treated with imatinib mesylate (IM). Patients were stratified into low-, intermediate- and high- risk groups according to three scoring systems (Sokal, Hasford and EUTOS), respectively. We compared the agreement of overall survival (OS), progression free survival (PFS), event free survival (EFS) in CML patients stratified by three prognostic scoring systems. The median for follow-up was 20.5 months.

RESULTS

EUTOS scoring system: In the low- and high-risk groups, the 5-year OS was 94.6% and 84.7% (P=0.011), 5-year EFS was 92.6% and 77.6% (P=0.001), and 5-year PFS was 95.3% and 82.4% (P=0.001), respectively. While stratified by Sokal or Hasford scoring system, there was no significant the correlation between low-, intermediate- and high- risk groups with the prognosis for CML patients (P>0.05). Compared with Sokal and Hasford scoring system, the outcome of EUTOS prognostic scoring system showed highly accordance with 5-year expect OS, PFS and EFS of CML patients.

CONCLUSION

EUTOS scoring system could predict the long-time outcome of CML-CP patients better than Sokal and Hasford scoring system. Chang of treatment may affect the prognostic value of EUTOS scoring system.

摘要

目的

回顾性分析三种预后评分系统对慢性粒细胞白血病(CML)慢性期(CP)患者预后评估的疗效。

方法

在这项回顾性队列研究中,我们收集了234例接受甲磺酸伊马替尼(IM)治疗的CP期CML患者。根据三种评分系统(Sokal、Hasford和EUTOS)分别将患者分为低、中、高风险组。我们比较了三种预后评分系统分层的CML患者总生存期(OS)、无进展生存期(PFS)、无事件生存期(EFS)的一致性。随访时间中位数为20.5个月。

结果

EUTOS评分系统:在低风险和高风险组中,5年总生存率分别为94.6%和84.7%(P = 0.011),5年无事件生存率分别为92.6%和77.6%(P = 0.001),5年无进展生存率分别为95.3%和82.4%(P = 0.001)。而按Sokal或Hasford评分系统分层时,低、中、高风险组与CML患者预后之间无显著相关性(P>0.05)。与Sokal和Hasford评分系统相比,EUTOS预后评分系统的结果与CML患者5年预期总生存率、无进展生存率和无事件生存率高度一致。

结论

EUTOS评分系统比Sokal和Hasford评分系统能更好地预测CML-CP患者的长期预后。治疗的改变可能会影响EUTOS评分系统的预后价值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验